Recent Developments in the Prevention and Treatment of Missing Data

Therapeutic Innovation and Regulatory Science

Volumn 48, Issue 1, 2014, Pages 68-80

  Mallinckrodt, C ^a   Roger, J ^b   Chuang Stein, C ^c   Molenberghs, G ^d,e   O'Kelly, M ^f   Ratitch, B ^f   Janssens, M ^d,e   Bunouf, P ^g  

^a ELI LILLY AND COMPANY   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c PFIZER INC   (United States)

^d HASSELT UNIVERSITY   (Belgium)

^e KU LEUVEN   (Belgium)

^f IQVIA   (United States)

^g INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

clinical trials; missing data; sensitivity analyses

Indexed keywords

ARTICLE; COMPUTER PROGRAM; DATA ANALYSIS; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL SOCIETY; MONITORING; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 84891536603     PISSN: 21684790     EISSN: 21649200     Source Type: Journal    
DOI: 10.1177/2168479013501310     Document Type: Article

References (20)

1. Mallinckrodt CHPreventing and Treating Missing Data in Longitudinal Clinical Trials: A Practical Guide. New York, NY: Cambridge University Press; 2013:.
2. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on missing data in confirmatory clinical trials. EMA/CPMP/EWP/1776/99 Rev. 1. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC500096793.pdf. Published July 2, 2010.
3. The Prevention and Treatment of Missing Data in Clinical Trials. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. Washington, DC: The National Academies Press; 2010:.
4. O'Neill RT,Temple R.The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.Clin Pharmacol Ther. 2012;91 (3): 550-554.
5. Molenberghs G,Kenward MGMissing Data in Clinical Studies. Chichester, UK: John Wiley; 2007:.
6. Mallinckrodt CH,Lane PW,Schnell D,Peng Y,Mancuso JP.Recommendations for the primary analysis of continuous end points in longitudinal clinical trials.Drug Inf J. 2008;42:305-319.
7. Mallinckrodt CH,Kenward MG.Conceptual considerations regarding choice of end points, hypotheses, and analyses in longitudinal clinical trials.Drug Inf J. 2009;43 (4): 449-458.
8. Mallinckrodt CH,Lin Q,Lipkovich I,Molenberghs G.A structured approach to choosing estimands and estimators in longitudinal clinical trials.Pharm Stat. 2012;11:456-461.
9. Carpenter J,Roger J,Kenward M.Analysis of longitudinal trials with missing data: a framework for relevant, accessible assumptions, and inference via multiple imputation.J Biopharm Stat. In press;:.
10. Verbeke G,Molenberghs G.Linear Mixed Models for Longitudinal Data. New York, NY: Springer; 2000:.
11. Fleming TR.Addressing missing data in clinical trials.Ann Intern Med. 2011;154:113-117.
12. Little R,Yau L.Intention-to-treat analysis for longitudinal studies with drop-outs.Biometrics. 1996;52 (4): 1324-1333.
13. CarpenterJRKenwardMG. Missing data in randomised controlled trials-a practical guide. http://missingdata.lshtm.ac.uk/downloads/rm04_jh17_mk.pdf. Published November 21, 2007. Accessed January 23, 2012.
14. RatitchBO'KellyM. Implementation of pattern-mixture models using standard SAS/STAT procedures. http://pharmasug.org/proceedings/2011/SP/PharmaSUG-2011-SP04.pdf. Accessed October 4, 2011.
15. Teshome B,Lipkovich I,Molenberghs G,Mallinckrodt CH.Placebo multiple imputation: a new approach to sensitivity analyses for incomplete longitudinal clinical trial data.Journal of Biopharmaceutical Statistics. In press;:.
16. Ratitch B,O'Kelly M,Tosiello RPharm Stat.
17. Goldstein DJ,Lu Y,Detke MJ,Wiltse C,Mallinckrodt C,Demitrack MA.Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.J Clin Psychopharmacol. 2004;24:389-399.
18. Detke MJ,Wiltse CG,Mallinckrodt CH,McNamara RK,Demitrack MA,Bitter I.Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.Eur Neuropsychopharmacol. 2004;14 (6): 457-470.
19. Hamilton M.A rating scale for depression.J Neurol Neurosurg Psychiatry. 1960;23:56-61.
20. SAS/STAT® 9.2. User's Guide. Cary, NC: SAS Institute; 2008:.